Chemotherapy, Adjuvant

"Chemotherapy, Adjuvant" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Drug therapy given to augment or stimulate some other form of treatment such as surgery or radiation therapy. Adjuvant chemotherapy is commonly used in the therapy of cancer and can be administered before or after the primary treatment.

Descriptor ID	D017024
MeSH Number(s)	E02.186.170 E02.319.170
Concept/Terms	Chemotherapy, Adjuvant Chemotherapy, Adjuvant Adjuvant Chemotherapy Drug Therapy, Adjuvant Adjuvant Drug Therapy

Below are MeSH descriptors whose meaning is more general than "Chemotherapy, Adjuvant".

Analytical, Diagnostic and Therapeutic Techniques and Equipment [E]
Therapeutics [E02]
Combined Modality Therapy [E02.186]
Chemotherapy, Adjuvant [E02.186.170]
Drug Therapy [E02.319]
Chemotherapy, Adjuvant [E02.319.170]

Below are MeSH descriptors whose meaning is related to "Chemotherapy, Adjuvant".

Below are MeSH descriptors whose meaning is more specific than "Chemotherapy, Adjuvant".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Chemotherapy, Adjuvant" by people in this website by year, and whether "Chemotherapy, Adjuvant" was a major or minor topic of these publications.

Bar chart showing 47 publications over 20 distinct years, with a maximum of 7 publications in 2017

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2002	0	1	1
2003	1	0	1
2005	0	1	1
2006	1	1	2
2007	0	2	2
2008	0	6	6
2009	0	1	1
2010	0	1	1
2012	0	2	2
2013	0	1	1
2014	0	2	2
2015	0	3	3
2016	0	1	1
2017	1	6	7
2018	1	2	3
2019	0	3	3
2020	0	3	3
2021	2	1	3
2024	0	2	2
2025	0	2	2

Below are the most recent publications written about "Chemotherapy, Adjuvant" by people in Profiles.

Matsuo K, Enserro DM, Wright JD, Roman LD, Powell MA, Miller DS, Nagel CI, Thaker PH, Mannel RS, Stuckey AR, Guntupalli SR, Sukumvanich P, Geller MA, Vargas R, Konecny GE, Warshal DP, Tewari KS, Spirtos NM, Pothuri B, Creasman WT, Mutch DG. Prospective assessment of prognostic significance of malignant peritoneal cytology in endometrial cancer: An NRG Oncology / Gynecologic Oncology Group study on GOG-210 protocol. Gynecol Oncol. 2025 Oct; 201:184-194.

View in: PubMed
Teplitsky SL, Cranford W, Kim JK, Bell S, Strup S, Allison D, Buchanan A, Myint Z, Strup SE, Martin F, Sood A, Kamat AM, McLouth CJ, Hensley PJ. Prognostic significance of pathologic response to neoadjuvant chemotherapy in muscle-invasive urothelial carcinoma of the bladder with histologic subtype. Urol Oncol. 2025 Sep; 43(9):521.e19-521.e27.

View in: PubMed
Sinicrope FA, Nelson GD, Saberzadeh-Ardestani B, Segovia DI, Graham RP, Wu C, Hagen CE, Shivji S, Savage P, Buchanan DD, Jenkins MA, Phipps AI, Swallow C, LeMarchand L, Gallinger S, Grant RC, Pai RK, Sinicrope SN, Yan D, Shanmugam K, Conner J, Cyr DP, Kirsch R, Banerjee I, Alberts SR, Shi Q, Pai RK. Use of Deep Learning to Evaluate Tumor Microenvironmental Features for Prediction of Colon Cancer Recurrence. Cancer Res Commun. 2024 05 23; 4(5):1344-1350.

View in: PubMed
Corsi NJ, Stephens A, Finati M, Malchow T, Morrison C, Davis M, Hares K, Corsi MP, Arora S, Chiarelli G, Cirulli GO, Autorino R, Sood A, Rogers C, Abdollah F. Testing the external validity of the POUT III trial (adjuvant platnium-based chemotherapy in upper tract urothelial carcinoma) in a North American cohort. Urol Oncol. 2024 06; 42(6):175.e19-175.e25.

View in: PubMed
Fukui J, White K, Frankland TB, Oshiro C, Wilkens L. Weight changes according to treatment in a diverse cohort of breast cancer patients. BMC Cancer. 2021 Sep 08; 21(1):1005.

View in: PubMed
Fujii T, Masuda H, Cheng YC, Yang F, Sahin AA, Naoi Y, Matsunaga Y, Raghavendra A, Sinha AK, Fernandez JRE, James A, Yamagishi K, Matsushima T, Schuetz R, Tripathy D, Tada S, Jackson RS, Noguchi S, Nakamura S, Acoba JD, Ueno NT. A 95-gene signature stratifies recurrence risk of invasive disease in ER-positive, HER2-negative, node-negative breast cancer with intermediate 21-gene signature recurrence scores. Breast Cancer Res Treat. 2021 Sep; 189(2):455-461.

View in: PubMed
Kim SR, Kotsopoulos J, Sun P, Bernardini MQ, Laframboise S, Ferguson SE, Rosen B, Narod SA, May T. The impacts of neoadjuvant chemotherapy and of cytoreductive surgery on 10-year survival from advanced ovarian cancer. Int J Gynaecol Obstet. 2021 Jun; 153(3):417-423.

View in: PubMed
Chambers LM, Kuznicki M, Yao M, Chichura A, Gruner M, Reizes O, Debernardo R, Rose PG, Michener C, Vargas R. Impact of antibiotic treatment during platinum chemotherapy on survival and recurrence in women with advanced epithelial ovarian cancer. Gynecol Oncol. 2020 12; 159(3):699-705.

View in: PubMed
Amnekar RV, Khan SA, Rashid M, Khade B, Thorat R, Gera P, Shrikhande SV, Smoot DT, Ashktorab H, Gupta S. Histone deacetylase inhibitor pre-treatment enhances the efficacy of DNA-interacting chemotherapeutic drugs in gastric cancer. World J Gastroenterol. 2020 Feb 14; 26(6):598-613.

View in: PubMed
Tran PT, Diaby V. Cost-Effectiveness Analysis of Adjuvant Neratinib Following Trastuzumab in Early-Stage HER2-Positive Breast Cancer. J Manag Care Spec Pharm. 2020 Feb; 26(2):221.

View in: PubMed

People

Explore

Similar Concepts

Top Journals